Ali Fattaey appointed Chief Executive Officer of MetaboMed
pharmafile | September 9, 2020 | Appointment | Research and Development |
MetaboMed has appointed Ali Fattaey, Ph.D. as its new Chief Executive Officer.
Fattaey has over 20 years experience in the industry. His most recent role was serving as the President and Chief Executive Officer of Curis, Inc in Boston and the company was dedicated to development of innovative medicines for patients with cancer.
Professor David Aviezer, MetaboMed’s chairman of the board, commented on the company’s new hire: “Ali brings to MetaboMed a proven track record in oncology drug development and a deep biotech industry skill set. He has led the development of several cancer therapeutics through all stages of discovery, development and regulatory process.
“MetaboMed is at the forefront of one of the most exciting new areas in cancer biology and drug discovery, with a significant foundation, a compelling vision, great people, deep science and a growing pipeline already in place. We look forward to Dr. Fattaey leading MetaboMed to the next stage as we near clinical development and continue to expand our presence in the U.S.”
He will replace Dr Simone Botti, the previous CEO, who will be joining the senior team of a large European VC fund, who said he believes his replacement will make the company a global leader in oncology.
Fattaey also commented on his new role: “I am excited to continue building on the world-class scientific foundation, exceptional team and culture of MetaboMed and lead the company into the next stage by establishing an equally strong clinical development dimension to the company. MetaboMed has already used its proprietary synthetic lethal screening platform to build an impressive pipeline of novel drug candidates addressing cancer metabolism targets, and we expect to initiate human trials for the first of these in the next year.
“We look forward to continuing and growing our ongoing pipeline discovery efforts in Israel, and our expansion in the Boston biotech community allows us to effectively execute the drug development and corporate aspects of our strategy.”